Australian generics association releases new code of practice

Generics/General | Posted 04/10/2013 post-comment0 Post your comment

Australia’s Generic Medicines Industry Association (GMiA) announced on 26 September 2013 the release of the draft third edition of the GMiA Code of Practice, which incorporates a number of new amendments.

Law V13C29

The code is principle based, providing guidance in a single document, on the different legislation, regulation and guidelines with which sponsors of generic medicines listed on the Australian Register of Therapeutic Goods (ARTG) comply.

This new draft includes recommendations from the Working Group on Promotion of Therapeutic Products as reported to the then Parliamentary Secretary, Ms Catherine King, in March 2011, as well as several other additions to the GMiA Code. These include issues such as removal of industry representatives on the Code Complaint Committee – increasing its independence, timing of reports and introduction of the concept of a ‘Complying Member’.

GMiA has released this draft third edition of its code for public consultation. The document can be found on the GMiA website at www.gmia.com.au/wp-content/uploads/2013/09/GMiA-Code-3rd-Edition-DRAFT-SEP13.pdf  Feedback from stakeholders can be submitted to GMiA at code@gmia.com.au until 31 October 2013.

Related articles

Australians pay too much for generics

Why choose generic medicines initiative launched in Australia

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.

Source: GMiA

comment icon Comments (0)
Post your comment
Related content
Generic drug growth in Brazil and Venezuela
53 MD002445
Generics/General Posted 15/09/2023
Pharmaceutical manufacturing companies in Brazil
91 AA007225
Generics/General Posted 26/08/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010